EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus

Jonas Martin iD, Qingyu Cheng, Sarah A Laurent, Franziska S Thaler, Anne Elisabeth Beenken, Edgar Meinl iD, Gerhard Krönke, Falk Hiepe, Tobias Alexander iD

International Journal of Molecular Sciences · 09.10.2024 · 25 (19) · 10845

DOI: 10.3390/ijms251910845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.10.2024. Verfasst von Jonas Martin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, B-Cell Maturation Antigen, Biomarkers, B-Cell Activating Factor. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, DFG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The BAFF-APRIL system is crucial for the pathogenesis of systemic lupus erythematosus (SLE) by promoting B cell survival, differentiation and the maintenance of humoral autoimmunity. Here, we investigated the relationship of BCMA expression on B cell subsets with its ligands BAFF and APRIL, together with soluble BCMA, and with clinical and serologic variables in a cohort of 100 SLE patients (86 under conventional and 14 under belimumab therapy) and 30 healthy controls (HCs) using multicolor flow cytometry and ELISA. We found that BCMA expression in SLE patients was significantly increased on all B cell subsets compared to HCs, with all examined components of the BAFF-APRIL system being upregulated. BCMA expression was significantly increased on switched and unswitched memory B cells compared to naïve B cells, both in HCs and SLE. BCMA expression on B cells correlated with plasmablast frequencies, serum anti-dsDNA antibodies and complement consumption, while soluble BCMA correlated with plasmablast frequency, highlighting its potential as a clinical biomarker. Belimumab treatment significantly reduced BCMA expression on most B cell subsets and soluble TACI and contributed to the inhibition of almost the entire BAFF-APRIL system and restoration of B cell homeostasis. These results provide insights into the complex dysregulation of the BAFF-APRIL system in SLE and highlight the therapeutic potential of targeting its components, particularly BCMA, in addition to its use as a biomarker for disease activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicB-Cell Maturation AntigenBiomarkersB-Cell Activating FactorTumor Necrosis Factor Ligand Superfamily Member 13Antibodies, Monoclonal, HumanizedHumansFemaleAdultMaleMiddle AgedAntibodies, AntinuclearB-LymphocytesB-Lymphocyte SubsetsCase-Control Studies

Stichwörter der Autor:innen

B cellsBAFFBCMASLETACIlupusplasma cells

Substanzen

B-Cell Maturation AntigenBiomarkersbelimumabB-Cell Activating FactorTumor Necrosis Factor Ligand Superfamily Member 13Antibodies, Monoclonal, HumanizedTNFSF13B protein, humanTNFRSF17 protein, humanTNFSF13 protein, humanAntibodies, Antinuclear

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, 10117 Berlin, Germany.
  • Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-Universität München, 80336 Munich, Germany.
  • Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität München, 82152 Martinsried, Germany.

ORCID-Profile: Jonas Martin, Edgar Meinl, Tobias Alexander

Förderung

  • Deutsche Forschungsgemeinschaft
  • DFG

Zitieren

APA

Martin, J., Cheng, Q., Laurent, S. A., Thaler, F. S., Beenken, A. E., Meinl, E., Krönke, G., Hiepe, F., & Alexander, T. (2024). B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 25(19), 10845. https://doi.org/10.3390/ijms251910845

Vancouver

Martin J, Cheng Q, Laurent SA, Thaler FS, Beenken AE, Meinl E, et al. B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2024;25(19):10845. doi:10.3390/ijms251910845

BibTeX
@article{Martin2024,
  author = {Martin, Jonas and Cheng, Qingyu and Laurent, Sarah A and Thaler, Franziska S and Beenken, Anne Elisabeth and Meinl, Edgar and Krönke, Gerhard and Hiepe, Falk and Alexander, Tobias},
  title = {B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {19},
  pages = {10845},
  doi = {10.3390/ijms251910845}
}
Kostenlos starten →